Bristol-Myers Can't Duck UMB Suit Targeting Drug Approvals
The Second Circuit on Thursday revived UMB Bank's suit alleging Bristol-Myers Squibb's slow-walking of the drug approval process caused investors to miss out on billions of dollars, rejecting the pharmaceutical giant's...To view the full article, register now.
Already a subscriber? Click here to view full article